Skip to main content
SpringerLink
Log in

Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia

A Cost-Effectiveness Analysis

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a rare but serious complication of heparin therapy. The diagnosis of HIT is difficult because its signs are non-specific and the heparin-platelet factor 4 (PF4) antibody test used to confirm the diagnosis is imprecise. Drugs used to treat HIT are costly and may carry an increased risk of bleeding.

Objective: To evaluate the cost effectiveness, from a societal perspective, of four treatment approaches for patients with suspected HIT within a US critical care setting.

Methods: A decision-tree was constructed for the management of a hypothetical cohort of critical care patients with possible evidence of HIT.

The management strategies were: (i) no antibody testing, continue heparin (No Test and Wait); (ii) antibody testing, continue heparin while test results pending (Test and Wait); (iii) antibody testing and switch to a direct thrombin inhibitor (DTI) while test results pending (Test and Switch); and (iv) no antibody testing but switch to a DTI (No Test and Switch). We used argatroban as the DTI in our analysis.

The outcomes were direct medical costs ($US; 2004 values), QALYs and incremental cost-effectiveness ratios (ICERs).

Results: Assuming an HIT prevalence of 3%, relative to less costly strategies, ordering an antibody test and switching patients to argatroban if the result was positive (Test and Wait) had an ICER of $US163 396/QALY. Pre-emptive switching to argatroban without antibody testing (No Test and Switch) was the most effective strategy but had an ICER of >$US1 million/QALY relative to the Test and Switch option. These results were highly sensitive to HIT prevalence among patients presenting with thrombocytopenia.

Assuming a willingness to pay of $US50 000 per QALY, the Test and Wait strategy became cost effective when the prior probability of HIT was 8%. At a prior probability of 12%, Test and Switch was cost effective, and at probabilities of HIT in the 60–75% range, No Test and Switch was cost effective. In two-way analysis, the probability of developing a thrombotic event was a key driver of treatment choice at specific HIT probabilities.

Conclusions: Testing for HIT in all typical critical care patients with thrombocytopenia is unlikely to represent a cost-effective management strategy. With increasing probability of HIT, strategies that include testing and a more rapid switch to a DTI appear more desirable. Accurate clinical judgment of the prior probability of HIT has a critical influence on the cost-effective management of HIT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121 (4): 535–555

    Article  PubMed  CAS  Google Scholar 

  2. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127 (2): 35S–45S

    Article  PubMed  CAS  Google Scholar 

  3. Verma AK, Levine M, Shalansky S J, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23 (6): 745–753

    Article  PubMed  Google Scholar 

  4. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005; 20 (4): 348–353

    Article  PubMed  Google Scholar 

  5. Warkentin TE, Greinacher A. Heparin-induced thrombo-cytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 311S–371S

    Article  PubMed  CAS  Google Scholar 

  6. Call JT, Deliargyris EN, Sane DC. Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004; 30 (3): 297–314

    Article  PubMed  CAS  Google Scholar 

  7. Thomson Corporation. Drug Topics Red book. Montvale (NJ): Thomson PDR, 2004: v

    Google Scholar 

  8. Gold MR, Siegel JE Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

  9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20): 1330–1335

    Article  PubMed  CAS  Google Scholar 

  10. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163 (20): 2518–2524

    Article  PubMed  Google Scholar 

  11. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96 (3): 846–851

    PubMed  CAS  Google Scholar 

  12. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban antico-agulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103 (14): 1838–1843

    Article  PubMed  CAS  Google Scholar 

  13. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163 (15): 1849–1856

    Article  PubMed  CAS  Google Scholar 

  14. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101 (5): 502–507

    Article  PubMed  CAS  Google Scholar 

  15. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106 (6): 629–635

    Article  PubMed  CAS  Google Scholar 

  16. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94 (1): 132–135

    PubMed  CAS  Google Scholar 

  17. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enox-aparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292 (1): 89–96

    Article  PubMed  CAS  Google Scholar 

  18. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95 (3): 315–328

    Article  PubMed  CAS  Google Scholar 

  19. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100 (15): 1593–1601

    Article  PubMed  CAS  Google Scholar 

  20. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108 (4 Suppl.): 276S–290S

    Article  PubMed  CAS  Google Scholar 

  21. Juergens CP, Semsarian C, Keech AC, et al. Hemorrhagic complications of intravenous heparin use. Am J Cardiol 1997; 80 (2): 150–154

    Article  PubMed  CAS  Google Scholar 

  22. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 1993; 11 (9): 874–881

    Google Scholar 

  23. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous mromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83 (1): 14–19

    PubMed  CAS  Google Scholar 

  24. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 287S–310S

    Article  PubMed  CAS  Google Scholar 

  25. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Haemost 2001; 12 (2): 141–149

    CAS  Google Scholar 

  26. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126 (11): 1415–1423

    PubMed  Google Scholar 

  27. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155 (7): 757–764

    Article  PubMed  CAS  Google Scholar 

  28. Devlin JW, Petitta A, Shepard AD, et al. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998; 18 (6): 1335–1342

    PubMed  CAS  Google Scholar 

  29. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130 (10): 789–799

    PubMed  CAS  Google Scholar 

  30. O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25 (3): 1017–1038

    Article  PubMed  Google Scholar 

  31. O’Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002; 20 (9): 603–615

    Article  PubMed  Google Scholar 

  32. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157 (3): 298–303

    Article  PubMed  CAS  Google Scholar 

  33. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13 (2): 89–102

    Article  PubMed  CAS  Google Scholar 

  34. Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995; 274 (2): 165–171

    Article  PubMed  CAS  Google Scholar 

  35. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22 (4): 340–349

    PubMed  Google Scholar 

  36. Sculpher M, Michaels J, McKenna M, et al. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12 (1): 104–125

    Article  PubMed  CAS  Google Scholar 

  37. Eckman MH, Greenfield S, Mac key WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analyses. JAMA 1995; 273 (9): 712–720

    Article  PubMed  CAS  Google Scholar 

  38. Brothers TE, Cox MH, Robison JG, et al. Prospective decision analysis modeling indicates that clinical decisions in vascular surgery often fail to maximize patient expected utility. J Surg Res 2004; 120 (2): 278–287

    Article  PubMed  Google Scholar 

  39. CEA Registry. Catalog of Preference Scores. Vol 2004 [online]. Available from URL: http://www.tufts-nemc.org/cearegistry/data/default.asp [Accessed 2007 Sep 24]

  40. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001; 32 (4): 964–972

    Article  PubMed  CAS  Google Scholar 

  41. Arias E. United States life tables, 2002. National Vital Statistics Reports; vol 53 no 6. Hyattsville (MD): National Center for Health Statistics, 2004

    Google Scholar 

  42. Center on the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston: Tufts-New England Medical Center, ICRHPS [online]. Available from URL: http://www.tufts-nemc.org/icrhps/resprog/cevr/ [Accessed 2007 Oct 25]

  43. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473–481

    PubMed  CAS  Google Scholar 

  44. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22 (5): 417–430

    PubMed  Google Scholar 

  45. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am See Hematol Educ Program) 2003: 497–519

    Google Scholar 

  46. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33 (7): 1879–1885

    Article  PubMed  CAS  Google Scholar 

  47. Hirahara T, Kubo N, Ohmura N, et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction [in Japanese]. J Cardiol 2004; 44 (2): 47–52

    PubMed  Google Scholar 

  48. Fanikos J, Stapinski C, Koo S, et al. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 2004; 94 (4): 532–535

    Article  PubMed  Google Scholar 

  49. Lube now N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (HIT) [abstract]. Blood 2002; 100: 502a

    Google Scholar 

  50. Lube now N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3 (11): 2428–2436

    Article  Google Scholar 

  51. Warkentin TW. Thrombotic end point for assessing argatroban therapy for heparin-induced thrombocytopenia: learning from secondary analyses of prospective studies. Chest 2006; 129 (6): 1396–1398

    Article  PubMed  CAS  Google Scholar 

  52. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (4): 353–365

    Article  PubMed  CAS  Google Scholar 

  53. Parody R, Oliver A, Souto JC, et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88 (11): ECR32

    PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.

Author information

Authors and Affiliations

  1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, 1620 Tremont Street, Boston, Massachusetts, 02120, USA

    Amanda R. Patrick, Wolfgang C. Winkelmayer, Jerry Avorn & Michael A. Fischer

Authors
  1. Amanda R. Patrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang C. Winkelmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jerry Avorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael A. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amanda R. Patrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patrick, A.R., Winkelmayer, W.C., Avorn, J. et al. Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia. Pharmacoeconomics 25, 949–961 (2007). https://doi.org/10.2165/00019053-200725110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725110-00005

Keywords

Search

Navigation